aspirin, not shared by other nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin (10) .
In the present article in focus, Nascimento-Silva et al. (Ref. 14a ; see p. C557 in this issue) confirm aspirin's role in activating HO-1 expression and offer a possible mechanistic explanation by introducing another HO-1 inducer, 15-epilipoxin A 4 , a lipid metabolite, and anti-inflammatory mediator of aspirin in vivo. With the use of a stable aspirin-triggered lipoxin A 4 analog (ATL-1), the authors find that HO-1 induction occurs both at the mRNA and protein levels and appears to be mediated by the activation of the G protein-coupled lipoxin A 4 (LXA 4 ) receptor. The functional relevance of HO-1 induction by LXA 4 is highlighted in a rescue experiment where the authors reverse LXA 4 -induced inhibition of VCAM and E-selectin expression by pretreating their endothelial cell culture system with SnPP, a competitive blocker of HO-1 activity. This is the first demonstration of synergism between the lipoxin and HO-1 pathways, which until now, due to lack of direct evidence, have been considered independent and unrelated anti-inflammatory signaling routes.
The observed increase in HO-1 protein in vitro elicited by aspirin in cultured endothelial cells is unlikely to be the result of ATL formation because ATL biosynthesis requires transcellular trafficking of lipid metabolites between endothelial cells and leukocytes (5), the latter not being present in the authors' experimental setup. However, this does not tarnish the importance of their findings. To the contrary, if aspirin were able to elevate HO-1 expression in vitro via additional ATL-independent pathways, how much more potent at HO-1 induction must this drug be in vivo, where ATL formation actually does take place?
Here is where nitric oxide (NO) comes into play. Endothelial NO synthase and NO were reported earlier to mediate HO-1 induction by aspirin in vitro (9, 10) . A look into last year's literature reveals that endothelial NO synthase as well as inducible NO synthase are also targets of ATL (15) . This suggests that more than one signaling route triggered by aspirin eventually leads to activation of NO formation and ensuing anti-inflammatory effects such as the inhibition of leukocyteendothelium interactions (15) .
The findings of the Fierro group have, of course, implications that go beyond endothelial function or dysfunction. Thus, of all the NSAIDs used, aspirin is surprisingly well tolerated, and previous studies found that the gastric safety of aspirin, at currently used anti-inflammatory doses, is quite high compared with other cyclooxygenase (COX) inhibitors (8) . Interestingly, this has been attributed in independent studies to the ability of aspirin to induce HO-1 in gastric tissue (3) and to generating ATL in the stomach (20) . LXA 4 and its carbon-15 epimer ATL have potent inhibitory effects on neutrophil chemotaxis, adherence, transmigration, and superoxide anion production. There is considerable evidence that neutrophils play a key role in the pathogenesis of NSAID-induced gastric damage and that LXA 4 formation, triggered by aspirin, exerts a gastroprotective influence (20) . Because acetylation of COX-2 in epithelial cells, followed by a shift in COX-2 activity toward 15R-HETE formation, is a necessary step in aspirin-triggered LXA 4 formation, COX-2 blockers have an inhibitory effect on LXA 4 formation under these conditions (5). This is reflected by clinical observations showing that the combination of aspirin and a selective COX-2 blocker results in greater gastric injury than that observed following the administration of either drug alone (20) .
Again, a similar pattern of action has been reported at the level of HO-1 expression, with aspirin but not COX-2 blockers being capable of inducing this gene in cultured gastric cells, presumably via NO-dependent pathways (4). As with vascular cells, one might expect even stronger inductions of gastric HO-1 caused by aspirin in vivo because aspirin-triggered LXA 4 is formed via transcellular biosynthetic pathways and requires the concerted action of different cell types.
Because of mixed study results, aspirin is currently not considered of therapeutic value in preeclampsia or gestational hypertension; however, the literature published to date consistently shows a protective effect of low-dose aspirin for women with risk factors for preeclampsia without an increase in bleeding complications, including placental abruption (6) . Whether HO-1 induction triggered by ATL might explain some of aspirin's beneficial effects under these conditions cannot be answered presently, but the functional profile of HO-1 characterized by anti-inflammatory as well as vasodilatory properties would certainly be in agreement with such a hypothesis (2) .
Interestingly, statins have also emerged very recently as inducers of HO-1 via unknown signaling routes (11, 13) , confirming once more that there is some truth to the description of aspirin as being "the poor man's statin" (18) .
From what is outlined above, it seems clear that future studies should, above all, address the in vivo relevance of LXA 4 -dependent HO-1 induction. With their demonstration that aspirin-triggered LXA 4 is a potent inducer of HO-1, Nascimento-Silva and coworkers have opened up a new chapter in HO-1 research. Because of numerous clinical implications and unanswered mechanistic questions, it bears the potential of attracting even more interested researchers into this exciting and still-young field of research.
